Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

7

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Vitamin k epoxide reductase complex subunit 1 isoform 1

5

Adrenergic receptor alpha

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

7

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1953

2

1954

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Myocardial infarction

5

Thromboembolic complications associated with atrial fibrillation

5

Venous thrombosis

5

Pheochromocytoma

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

5

Primary

5

Palliative

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

5

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Eisai

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

7

PUBCHEM

7

CAS

5

ChEMBL

5

DRUG BANK

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

BLOOD AND BLOOD FORMING ORGANS

1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTITHROMBOTIC AGENTS

1

PERIPHERAL VASODILATORS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTITHROMBOTIC AGENTS

1

PERIPHERAL VASODILATORS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other peripheral vasodilators

1

Vitamin K antagonists

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

WARFARIN

5Q7ZVV76EI

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1954

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Vitamin k epoxide reductase complex subunit 1 isoform 1

Conditions:

Myocardial infarction

Venous thrombosis

Thromboembolic complications associated with atrial fibrillation

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Warfarin is marketed under the brand name Coumadin among others. Coumadin (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting...

vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4-hydroxycoumarin and is a racemic mixture of the R- and S-enantiomers. Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. It is also indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient’s VKORC1 genotype. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.

PHENOXYBENZAMINE

0TTZ664R7Z

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First approved in 1953

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Adrenergic receptor alpha

Conditions:

Pheochromocytoma

Phenoxybenzamin (marketed under the trade name Dibenzyline) is an alpha-adrenergic antagonist with long duration of action. It is indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is exce...

ssive, it may be necessary to use a beta-blocking agent concomitantly. Phenoxybenzamine produces its therapeutic actions by blocking alpha receptors, leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. Phenoxybenzamine hydrochloride can produce and maintain “chemical sympathectomy” by oral administration. It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures. It has no effect on the parasympathetic system. Twenty to percent of orally administered phenoxybenzamine appears to be absorbed in the active form. The half-life of orally administered phenoxybenzamine hydrochloride is not known; however, the half-life of intravenously administered drug is approximately 24 hours. Demonstrable effects with intravenous administration persist for at least 3 to 4 days, and the effects of daily administration are cumulative for nearly a week. The following adverse reactions have been observed, but there are insufficient data to support an estimate of their frequency: Postural hypotension, tachycardia, inhibition of ejaculation, nasal congestion, and miosis. These so-called “side effects” are actually evidence of adrenergic blockade and vary according to the degree of blockade. Miscellaneous: Gastrointestinal irritation, drowsiness, fatigue.

WARFARIN SODIUM ISOPROPANOL HYDRATE COMPLEX

YH7WZD4PG3

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1954

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Vitamin k epoxide reductase complex subunit 1 isoform 1

Conditions:

Myocardial infarction

Venous thrombosis

Thromboembolic complications associated with atrial fibrillation

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Warfarin is marketed under the brand name Coumadin among others. Coumadin (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting...

vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4-hydroxycoumarin and is a racemic mixture of the R- and S-enantiomers. Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. It is also indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient’s VKORC1 genotype. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.

WARFARIN POTASSIUM

I47IU4FOCO

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1954

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Vitamin k epoxide reductase complex subunit 1 isoform 1

Conditions:

Myocardial infarction

Venous thrombosis

Thromboembolic complications associated with atrial fibrillation

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Warfarin is marketed under the brand name Coumadin among others. Coumadin (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting...

vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4-hydroxycoumarin and is a racemic mixture of the R- and S-enantiomers. Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. It is also indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient’s VKORC1 genotype. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.

WARFARIN SODIUM

6153CWM0CL

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1954

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Vitamin k epoxide reductase complex subunit 1 isoform 1

Conditions:

Myocardial infarction

Venous thrombosis

Thromboembolic complications associated with atrial fibrillation

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Warfarin is marketed under the brand name Coumadin among others. Coumadin (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting...

vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4-hydroxycoumarin and is a racemic mixture of the R- and S-enantiomers. Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. It is also indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient’s VKORC1 genotype. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.

WARFARIN SODIUM ISOPROPANOL COMPLEX

4V2UBU7H8W

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1954

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Vitamin k epoxide reductase complex subunit 1 isoform 1

Conditions:

Myocardial infarction

Venous thrombosis

Thromboembolic complications associated with atrial fibrillation

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Warfarin is marketed under the brand name Coumadin among others. Coumadin (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting...

vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4-hydroxycoumarin and is a racemic mixture of the R- and S-enantiomers. Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. It is also indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient’s VKORC1 genotype. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.

PHENOXYBENZAMINE HYDROCHLORIDE

X1IEG24OHL

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First approved in 1953

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Adrenergic receptor alpha

Conditions:

Pheochromocytoma

Phenoxybenzamin (marketed under the trade name Dibenzyline) is an alpha-adrenergic antagonist with long duration of action. It is indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is exce...

ssive, it may be necessary to use a beta-blocking agent concomitantly. Phenoxybenzamine produces its therapeutic actions by blocking alpha receptors, leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. Phenoxybenzamine hydrochloride can produce and maintain “chemical sympathectomy” by oral administration. It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures. It has no effect on the parasympathetic system. Twenty to percent of orally administered phenoxybenzamine appears to be absorbed in the active form. The half-life of orally administered phenoxybenzamine hydrochloride is not known; however, the half-life of intravenously administered drug is approximately 24 hours. Demonstrable effects with intravenous administration persist for at least 3 to 4 days, and the effects of daily administration are cumulative for nearly a week. The following adverse reactions have been observed, but there are insufficient data to support an estimate of their frequency: Postural hypotension, tachycardia, inhibition of ejaculation, nasal congestion, and miosis. These so-called “side effects” are actually evidence of adrenergic blockade and vary according to the degree of blockade. Miscellaneous: Gastrointestinal irritation, drowsiness, fatigue.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1